These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 16160934)

  • 1. Bile acid sequestrants: their use in combination with other lipid-lowering agents.
    Mandeville WH; Arbeeny C
    IDrugs; 1999 Mar; 2(3):237-42. PubMed ID: 16160934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
    Hou R; Goldberg AC
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation rates of cholesterol-lowering medications: implications for primary care.
    Hiatt JG; Shamsie SG; Schectman G
    Am J Manag Care; 1999 Apr; 5(4):437-44. PubMed ID: 10387383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of currently available modes of therapy in reaching lipid goals.
    Spratt KA; Denke MA
    J Am Osteopath Assoc; 2004 Sep; 104(9 Suppl 7):S14-6. PubMed ID: 15467019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-lowering medications.
    Rodenburg J; Vissers MN; Daniels SR; Wiegman A; Kastelein JJ
    Pediatr Endocrinol Rev; 2004 Nov; 2 Suppl 1():171-80. PubMed ID: 16456497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol.
    Corsini A; Windler E; Farnier M
    Eur J Cardiovasc Prev Rehabil; 2009 Feb; 16(1):1-9. PubMed ID: 19237992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The economics of hypercholesterolemia and lipid-lowering therapy: a brief historical tour.
    Oster G
    Value Health; 1998 Sep; 1(3):159-65. PubMed ID: 16674346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia.
    Avisar I; Brook JG; Wolfovitz E
    Eur J Intern Med; 2008 May; 19(3):203-8. PubMed ID: 18395165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.
    Bays HE; Davidson M; Jones MR; Abby SL
    Am J Cardiol; 2006 Apr; 97(8):1198-205. PubMed ID: 16616026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The patient at risk: who should we be treating?
    Leitersdorf E
    Br J Clin Pract Suppl; 1994 Dec; (77):24-7. PubMed ID: 19496269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R; Mahajan M; Singh B; Bal BS; Kant R
    J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
    Davidson M
    Am J Cardiol; 2008 Dec; 102(12A):19L-27L. PubMed ID: 19084086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid lowering treatment patterns and goal attainment in Nordic patients with hyperlipidemia.
    Svilaas A; Strandberg T; Eriksson M; Hildebrandt P; Westheim A
    Scand Cardiovasc J; 2008 Aug; 42(4):279-87. PubMed ID: 18609053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing dyslipidemia in chronic kidney disease.
    Harper CR; Jacobson TA
    J Am Coll Cardiol; 2008 Jun; 51(25):2375-84. PubMed ID: 18565393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-lowering medications for children and adolescents.
    Miller ML; Wright CC; Browne B
    J Clin Lipidol; 2015; 9(5 Suppl):S67-76. PubMed ID: 26343214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of niacin and simvastatin combination therapy.
    Bays H
    Am J Cardiol; 2008 Apr; 101(8A):3B-8B. PubMed ID: 18375239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice.
    Kamal-Bahl SJ; Burke T; Watson D; Wentworth C
    Am J Cardiol; 2007 Feb; 99(4):530-4. PubMed ID: 17293198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.